secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001628280-24-033437
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance
------------------------------------------------------------------------------

- Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.
- Received Nasdaq Staff deficiency notice on May 20, 2024 for non-compliance with Listing Rule 5550(b)(1).
- On July 29, 2024, Nasdaq granted a 180-day extension to November 18, 2024 to regain compliance.
- Company submitted a compliance plan; no assurance it will regain compliance by the deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/0001628280-24-033437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/avtx-20240729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer